Abstract

Fanconi anemia (FA) is a rare genetic disease caused by mutations in genes whose protein products are involved in important cell processes such as replication, cell cycle control and repair of DNA damage. FA is characterized by congenital malformations, bone marrow failure and high risk of cancer. Phenotypic symptoms, present in about 75% of patients, most often include such abnormalities as short stature, microcephaly, thumb and radial side of the limb defects, abnormal skin pigmentation, gastrointestinal and genitourinary defects. Progressive bone marrow failure occurs in the first decade of life, often initially with leukopenia or thrombocytopenia. The most common cancers occurring in patients with FA are myelodysplastic syndromes and acute myeloid leukemia, as well as solid tumors of the head and neck, skin, gastrointestinal system and genitourinary system. So far, 22 genes of Fanconi anemia (FANC) have been identified, which are located on the autosomal chromosomes, except for FANCB, which is located on the X chromosome. Protein products of FANC genes are the elements of Fanconi anemia pathway, which regulates DNA damage repair systems. Genetic diagnostics of Fanconi anemia should start by testing crosslinking agents: mitomycin C (MMC) or diepoxybutane (DEB) assuring differential diagnosis of chromosome instability syndromes. In patients with Fanconi anemia, an increased number of chromosomal gaps and breaks as well as specific radial structures are observed. In order to detect a mutation underlying Fanconi anemia, molecular techniques should be used, preferentially next generation sequencing (NGS).

References

• 1. Alter B.P.: Diagnosis, genetics, and management of inherited bonemarrow failure syndromes. Hematology Am. Soc. Hematol. Educ. Program,2007; 1: 29–39
  Google Scholar
• 2. Alter B.P., Caruso J.P., Drachtman R.A., Uchida T., Velagaleti G.V.,Elghetany M.T.: Fanconi anemia: Myelodysplasia as a predictor ofoutcome. Cancer Genet. Cytogenet., 2000; 117: 125–131
  Google Scholar
• 3. Alter B.P., Giri N., Savage S.A., Peters J.A., Loud J.T., Leathwood L.,Carr A.G., Greene M.H., Rosenberg P.S.: Malignancies and survival patternsin the National Cancer Institute inherited bone marrow failuresyndromes cohort study. Br. J. Haematol., 2010; 150: 179–188
  Google Scholar
• 4. Asur R.S., Kimble D.C., Lach F.P., Jung M., Donovan F.X., Kamat A.,Thomas J.W., Park M., Chines P., Vlachost A., Auerbach A.D., SmogorzewskaA., Chandrasekharappa S.C.: Somatic mosaicism of an intragenicFANCB duplication in both fibroblast and peripheral blood cellsobserved in a Fanconi anemia patient leads to milder phenotype. Mol.Genet. Genomic Med., 2018; 6: 77–91
  Google Scholar
• 5. Auerbach A.: Diagnosis of Fanconi anemia by diepoxybutane analysis.Curr. Protoc. Hum. Genet., 2016; 85: 1–23
  Google Scholar
• 6. Auerbach A.D.: Fanconi anemia and its diagnosis. Mut. Res., 2009;668: 4–10
  Google Scholar
• 7. Auerbach A.D., Min Z., Ghosh R., Pergament E., Verlinsky Y., NicolasH., Boué J.: Clastogen-induced chromosomal breakage as a markerfor first trimester prenatal diagnosis of Fanconi anemia. Hum. Genet.,1986; 73: 86–88
  Google Scholar
• 8. Berger R., Jonveaux P.: Clonal chromosome abnormalities in Fanconianemia. Hematol. Cell Ther., 1996; 38: 291–296
  Google Scholar
• 9. Berliner J.L., Fay A.M.: Practice issues subcommittee of the NationalSociety of Genetic Counselors’ Familial Cancer Risk Counseling SpecialInterest Group: Risk assessment and genetic counseling for hereditarybreast and ovarian cancer: Recommendations of the National Societyof Genetic Counselors. J. Genet. Couns., 2007; 16: 241–260
  Google Scholar
• 10. Bogliolo M., Lyakhovich A., Callén E., Castellà M., Cappelli E.,Ramírez M., Creus A., Marcos R., Kalb R., Neveling K., Schindler D.,Surralle J.: Histone H2AX and Fanconi anemia FANCD2 function inthe same pathway to maintain chromosome stability. EMBO, 2007;26: 1340–1351
  Google Scholar
• 11. Bogliolo M., Surralles J.: Fanconi anemia: A model disease forstudies on human genetics and advanced therapeutics. Curr. Opin.Genet. Dev., 2015; 33: 32–40
  Google Scholar
• 12. Callén E., Casado J.A., Tischkowitz M.D., Bueren J.A., Creus A., MarcosR., Dasí A., Estella J.M., Muñoz A., Ortega J.J., de Winter J., JoenjeH., Schindler D., Hanenberg H., Hodgson S.V., Mathew C.G., SurrallésJ.: A common founder mutation in FANCA underlies the world’s highestprevalence of Fanconi anemia in Gypsy families from Spain. Blood,2005; 105: 1946–1949
  Google Scholar
• 13. Castella M., Pujol R., Callén E., Trujillo J., Casado J., Gille H., LachF., Auerbach A., Schindler D., Benítez J., Porto B., Ferro T., Muñoz A.,Sevilla J., Madero L. i wsp.: Origin, functional role, and clinical impactof Fanconi anemia FANCA mutations. Blood, 2011; 117: 3759–3769
  Google Scholar
• 14. Chandra S., Levran O., Jurickova I., Maas C., Kapur R., SchindlerD., Henry R., Milton K., Batish S.D., Cancelas J.A., Hanenberg H., AuerbachA.D., Williams D.A.: A rapid method for retrovirus-mediatedidentification of complementation groups in Fanconi anemia patients.Mol. Ther., 2005; 12: 976–984
  Google Scholar
• 15. Che R., Zhang J., Nepal M., Han B., Fei P.: Multifaceted Fanconianemia signaling. Trends Genet., 2018; 34: 171–183
  Google Scholar
• 16. Cheung R.S., Taniguchi T.: Recent insights into the molecular basisof Fanconi anemia: genes, modifiers, and drivers. Int. J. Hematol.,2017; 106: 335–344
  Google Scholar
• 17. Chrzanowska K., Gregorek H., Dembowska-Bagińska B., KalinaM.A., Digweed M.: Nijmegen breakage syndrome (NBS). Orphanet J.Rare Dis., 2012; 7: 7: 13
  Google Scholar
• 18. Cioc A.M., Wagner J.E., MacMillan M.L., DeFor T., Hirsch B.: Diagnosisof myelodysplastic syndrome among a cohort of 119 patientswith Fanconi anemia: morphologic and cytogenetic characteristics.Am. J. Clin. Pathol., 2010; 133: 92–100
  Google Scholar
• 19. Digweed M., Hoehn H., Sperling K.: Milestones in Fanconi anemiaresearch. Monogr. Hum. Genet., 2007; 15: 23–38
  Google Scholar
• 20. Dokal I.: Inherited bone marrow failure syndromes. J. Hematopathol.,2011, 4, 53–60
  Google Scholar
• 21. Duxin J.P., Walter J.C.: What is the DNA repair defect underlyingFanconi anemia. Curr. Opin. Cell Biol., 2015; 37: 49–60
  Google Scholar
• 22. Esai Selvan M., Klein K.J., Gümüs Z.H.: Rare, pathogenic germlinevariants in Fanconi anemia genes increase risk for squamous lungcancer. Clin. Cancer Res., 2019; 25: 1517–1525
  Google Scholar
• 23. Faivre L., Guardiola P., Lewis C., Dokal I., Ebell W., Zatterale A., AltayC., Poole J., Stones D., Kwee M.L., van Weel-Sipman M., Havenga C., Morgan N., de Winter J., Digweed M. i wsp.: Assotiation of complementationgroup and mutation type with clinical outcome in Fanconianemia. European Fanconi Anemia Research Group. Blood, 2000; 96:4064–4070
  Google Scholar
• 24. Faivre L., Portnoï M.F., Pals G., Stoppa-Lyonnet D., Le Merrer M.,Thauvin-Robinet C., Huet F., Mathew C.G., Joenje H., Verloes A., BaumannC.: Should chromosome breakage studies be performed in patientswith VACTERL association? Am. J. Med. Genet. A, 2005; 137:55–58
  Google Scholar
• 25. Fanconi G.: Familiäre infantile perniziosaartige Anämie (perniziösesBlutbild und Konsitution). Jahrb. f. Kinderheilk., 1927; 117: 257–280
  Google Scholar
• 26. Gille J.J., Foor K., Kerkhoven L., Ameziane N., Joenje H., Winter J.P.:Diagnosis of Fanconi anemia: mutation analysis by Multiplex Ligation-Dependent Probe Amplification and PCR-based Sanger sequencing.Anemia, 2012; 2012: 603253
  Google Scholar
• 27. Glanz A., Fraser C.: Spectrum of anomalies in Fanconi anaemia. J.Med. Genet., 1982; 19: 412–416
  Google Scholar
• 28. Gluckman E., Broxmeyer HA., Auerbach A.D., Friedman H.S., DouglasG.W., Devergie A., Esperou H., Thierry D., Socie G., Lehn P., M.D.,Cooper S., English D., Kurtzberg J., Bard J., Boyse E.: Hematopoieticreconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N. Engl. J. Med., 1989;321: 1174–1178
  Google Scholar
• 29. Göhring G., Karow A., Steinemann D., Wilkens L., Lichter P., ZeidlerC., Niemeyer C., Welte K., Schlegelberger B.: Chromosomal aberrationsin congenital bone marrow failure disorders – an early indicator forleukemogenesis? Ann. Hematol., 2007; 86, 733–739
  Google Scholar
• 30. Grompe M., D’Andrea A.: Fanconi anemia and DNA repair. Hum.Mol. Genet., 2001; 10: 2253–2259
  Google Scholar
• 31. Gross M., Hanenberg H., Lobitz S., Friedl R., Herterich S., DietrichR., Gruhn B., Schindler D., Hoehn H.: Reverse mosaicism in Fanconianemia: natural gene therapy via molecular self-correction. Cytogenet.Genome Res., 2002; 98: 126–135
  Google Scholar
• 32. Hays, L.: Laboratory Diagnostics in Fanconi Anemia: Guidelinesfor Diagnosis and Management (4th ed.). 2014; Fanconi Anemia ResearchFund
  Google Scholar
• 33. Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., De Die-Smulders C., Persky N., Grompe M., Joenje H., Pals G., Ikeda H., FoxE.A., D’Andrea A.D.: Biallelic inactivation of BRCA2 in Fanconi anemia.Science, 2002; 297: 606–609
  Google Scholar
• 34. Huret J.L., Ahmad M., Arsaban M., Bernheim A., Cigna J., DesanglesF., Guignard J.C., Jacquemot-Perbal M.C., Labarussias M., Leberre V.,Malo A., Morel-Pair C., Mossafa H., Potier J.C., Texier G., i wsp.: Atlasof genetics and cytogenetics in oncology and haematology in 2013.Nucleic Acids Res., 2013; 41: 920–924
  Google Scholar
• 35. Jones M.J., Huang T.T.: The Fanconi anemia pathway in replicationstress and DNA crosslink repair. Cell. Mol. Life Sci., 2012; 69: 3963–3974
  Google Scholar
• 36. Kimble D.C., Lach F.P., Gregg S.Q., Donovan F.X., Flynn E.K., KamatA., Young A., Vemulapalli M., Thomas J.W., Mullikin J.C., AuerbachA.D., Smogorzewska A., Chandrasekharappa S.C.: A comprehensiveapproach to identification of pathogenic FANCA variants in Fanconianemia patients and their families. Hum. Mutat. 2018; 39: 237–254
  Google Scholar
• 37. Kitao H., Takata M.: Fanconi anemia: a disorder in the DNA damageresponse. Int. J. Hematol., 2011; 93: 417–424
  Google Scholar
• 38. Koczorowska A.M., Białkowska A., Kluzek K., Zdzienicka M.Z.:Rola białek niedokrwistości Fanconiego w naprawie DNA i utrzymaniustabilności genomu. Postępy Hig. Med. Dośw., 2014; 68: 459–472
  Google Scholar
• 39. Kutler D.I., Auerbach A.D., Satagopan J., Giampietro P.F., BatishS.D., Huvos A.G., Goberdhan A., Shah J.P., Singh B.: High incidence ofhead and neck squamous cell carcinoma in patients with Fanconi anemia.Arch. Otolaryngol. Head Neck Surg., 2003; 129: 106–112
  Google Scholar
• 40. Kutler D.I., Singh B., Satagopan J., Batish S.D., Berwick M., GiampietroP.F., Hanenberg H., Auerbach A.D.: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood, 2003;101: 1249–1256
  Google Scholar
• 41. Lelij P., Oostra A., Rooimans M., Joenje H., Winter J.: Diagnosticoverlap between Fanconi anemia and the cohesinopathies: Robertssyndrome and Warsaw Breakage Syndrome. Anemia, 2010; 2010:565268
  Google Scholar
• 42. Liu J.M., Buchwald M., Walsh C.E., Young N.S.: Fanconi anemia andnovel strategies for therapy. Blood, 1994; 84: 3995–4007
  Google Scholar
• 43. Lo Ten Foe J.R., Kwee M.L., Rooimans M.A., Oostra A.B., VeermanA.J., van Weel M., Pauli R.M., Shahidi N.T., Dokal I., Roberts I., Altay C.,Gluckman E., Gibson R.A., Mathew C.G., Arwert F., Joenje H.: Somaticmosaicism in Fanconi anemia: molecular basis and clinical significance.Eur. J. Hum. Genet., 1997; 5: 137–148
  Google Scholar
• 44. MacMillan M.L., Wagner J.E.: Haematopoeitic cell transplantationfor Fanconi anaemia – when and how? Br. J. Haematol., 2010; 149: 14–21
  Google Scholar
• 45. Mahon S.M.: Breast cancer risk associated with CHEK2 mutations.Oncol. Nurs. Forum., 2014; 41: 692–694
  Google Scholar
• 46. Mathew C.G.: Fanconi anaemia genes and susceptibility to cancer.Oncogene, 2006; 25: 5875–5884
  Google Scholar
• 47. Meyer S., Bristow C., Wappett M., Pepper S., Whetton A.D., HanenbergH., Neitzel H., Wlodarski M.W., Ebell W., Tönnies H.: Fanconianemia (FA)-associated 3q gains in leukemic transformation consistentlytarget EVI1, but do not affect low TERC expression in FA. Blood,2011; 117: 6047–6050
  Google Scholar
• 48. Meyer S., Neitzel H., Tönnies H.: Chromosomal aberrations associatedwith clonal evolution and leukemic transformation in Fanconianemia: Clinical and biological implications. Anemia, 2012; 2012:349837
  Google Scholar
• 49. Mitchell R., Wagner J.E., Hirsch B., DeFor T.E., Zierhut H., MacMillanM.L.: Haematopoietic cell transplantation for acute leukaemiaand advanced myelodysplastic syndrome in Fanconi Anaemia. Br. J.Haematol., 2014; 164: 384–395
  Google Scholar
• 50. Moreira C.F., Brito L.C.Jr., Lemos J.A.: Flow cytometry for diepoxybutanetest analysis. Genet. Mol. Res., 2008; 7: 1353–1359
  Google Scholar
• 51. Morgan N.V., Tipping A.J., Joenje H., Mathew G.: High frequency oflarge deletions in Fanconi anemia group A gene. Am. J. Hum. Genet.,1999; 65: 1330–1341
  Google Scholar
• 52. Nepal M., Che R., Zhang J., Ma C., Fei P.: Fanconi anemia signalingand cancer. Trends Cancer, 2017; 3: 840–856
  Google Scholar
• 53. Neveling K., Bechtold A., Hoehn H.: Genetic instability syndromeswith progeroid features. Z. Gerontol. Geriat., 2007; 40: 339–348
  Google Scholar
• 54. Neveling K., Endt D., Hoehn H., Schindler D.: Genotype-phenotypecorrelations in Fanconi anemia. Mutat. Res., 2009; 668: 73–91
  Google Scholar
• 55. Niedernhofer L.J., Lalai A.S., Hoejimakers J.H.J.: Fanconi anemia(Cross)linked to DNA repair. Cell, 2005; 123: 1191–1198
  Google Scholar
• 56. Nik-Zainal S., Alexandrov L.B., Wedge D.C., Loo P.V., GreenmanC.D., Raine K., Jones D., Hinton J., Marshall J., Stebbings L.A., MenziesA., Martin S., Leung K., Chen L. i wsp.: Mutational processes moldingthe genomes of 21 breast cancers. Cell, 2012; 149: 979–993
  Google Scholar
• 57. Niraj J., Färkkilä A., D’Andrea A.D.: The Fanconi anemia pathwayin cancer. Annu. Rev. Cancer Biol., 2019; 3: 457–478
  Google Scholar
• 58. Oestergaard V.H., Langevin F., Kuiken H.J., Pace P., NiedzwiedzW., Simpson L.J., Ohzeki M., Takata M., Sale J.E., Patel K.J.: Deubiquitinationof FANCD2 is required for DNA crosslink repair. Mol. Cell.,2007; 28: 798–809
  Google Scholar
• 59. Oostra A., Nieuwint A., Joenje H., Winter J.: Diagnosis of Fanconianemia: Chromosomal breakage analysis. Anemia, 2012; 2012: 238731
  Google Scholar
• 60. Perikh S., Bessler M.: Recent insights into inherited bone marrowfailure syndromes. Curr. Opin. Pediatr., 2012; 24: 23–32
  Google Scholar
• 61. Pinto F.O., Leblanc T., Chamousset D., Le Roux G., Brethon B.,Cassinat B., Larghero J., de Villartay J.P., Stoppa-Lyonnet D., Baruchel A., Socié G., Gluckman E., Soulier J.: Diagnosis of Fanconi anemia inpatients with bone marrow failure. Haematologica, 2009; 94: 487-495
  Google Scholar
• 62. Prandota J., Haus O.: Aberracje chromosomów w anemii aplastycznejFanconiego. Ped. Pol., 1985; 60: 87–89
  Google Scholar
• 63. Rantala J., Platten U., Lindgren G., Nilsson B., Arver B., LindblomA., Brandberg Y.: Risk perception after genetic counseling in patientswith increased risk of cancer. Hered. Cancer Clin. Pract., 2009; 7: 1–14
  Google Scholar
• 64. Rao V.B., Kerketta L., Korgaonkar S., Ghosh K.: Differentiationof Nijmegen breakage syndrome from Fanconi anemia. Genet. Mol.Res., 2007; 6: 622–626
  Google Scholar
• 65. Rickman K., Smogorzewska A.: Advances in understanding DNAprocessing and protection at stalled replication forks. J. Cell Biol.2019; 218: 1096–1107
  Google Scholar
• 66. Rio P., Navarro S., Bueren J.A.: Advances in the gene therapy forFanconi anemia. Hum. Gene Ther., 2018; 29: 1114–1123
  Google Scholar
• 67. Risitano A.M., Marotta S., Calzone R., Grimaldi F., Zatterale A.:Twenty years of the Italian Fanconi Anemia Registry: Where we standand what remains to be learned. Hematologica, 2016; 101: 319–327
  Google Scholar
• 68. Rosenberg P.S., Greene M.H., Alter B.P.: Cancer incidence in personswith Fanconi anemia. Blood, 2003; 101: 822–826
  Google Scholar
• 69. Sareen A., Chaudhury I., Adams N., Sobeck A.: Fanconi anemiaproteins FANCD2 and FANCI exhibit different DNA damage responsesduring S-phase. Nucleic Acids Res., 2012; 40: 8425–8439
  Google Scholar
• 70. Sasaki M.S., Tonomura A.: A high susceptibility of Fanconi’s anemiato chromosome breakage by DNA cross-linking agents. CancerRes., 1973; 33: 1829–1836
  Google Scholar
• 71. Savage S.A., Walsh M.F.: Myelodysplastic syndrome, acute myeloidleukemia, and cancer surveillance in Fanconi anemia. Hematol. Oncol.Clin. N. Am., 2018; 32: 657–668
  Google Scholar
• 72. Schimamura A., Alter B.P.: Pathophysiology and managementof inherited bone marrow failure syndromes. Blood Rev., 2010; 24:101–122
  Google Scholar
• 73. Schroeder T.M.: Genetically determined chromosome instabilitysyndromes. Cytogenet. Cell Genet., 1982; 33: 119–132
  Google Scholar
• 74. Shah S., Kim Y., Ostrovnaya I., Murali R., Schrader K.A., Lach F.P.,Sarrel K., Rau-Murthy R., Hansen N., Zhang L., Kirchhoff T., StadlerZ., Robson M., Vijai J., Offit K., Smogorzewska A.: Assessment of SLX4mutations in hereditary breast cancers. PLoS One, 2013; 8: 1–5
  Google Scholar
• 75. Shukla P., Ghosh K., Vundinti R.: Current and emerging therapeuticstrategies for Fanconi anemia. HUGO J., 2012; 6: 1–8
  Google Scholar
• 76. Shukla P., Rao A., Ghosh K., Vundinti R.: Identification of a novellarge intragenic deletion in a family with Fanconi anemia: First molecular report from India and review of literature. Gene, 2013; 518:470–475
  Google Scholar
• 77. Strathdee C.A., Gavish H., Shannon W.R., Buchwald M.: Cloningof cDNAs for Fanconi’s anaemia by functional complementation. Nature,1992; 356: 763–767
  Google Scholar
• 78. Struewing J.P., Brody L.C., Erdos M.R., Kase R.G., Giambarresi T.R.,Smith S.A., Collins F.S., Tucker M.A.: Detection of eight BRCA1 mutationsin 10 breast/ovarian cancer families, including 1 family withmale breast cancer. Am. J. Hum. Genet., 1995; 57: 1–7
  Google Scholar
• 79. Su X., Huang J.: The Fanconi anemia pathway and DNA interstrandcross-link repair. Protein Cell, 2011; 2: 704–711
  Google Scholar
• 80. Taylor A.M., Rothblum-Oviatt C., Ellis N.A., Hickson I.D., MeyerS., Crawford T.O., Smogorzewska A., Pietrucha B., Weemaes C., StewartG.S.: Chromosome instability syndromes. Nat. Rev. Dis. Primers,2019; 5: 64
  Google Scholar
• 81. Tischkowitz M., Capanu M., Sabbaghian N., Li L., Liang X., ValléeM.P., Tavtigian S.V., Concannon P., Foulkes W.D., Bernstein L., WECAREStudy Collaborative Group, Bernstein J.L., Begg C.B.: Rare germlinemutations in PALB2 and breast cancer risk: A population-based study.Hum. Mutat., 2012; 33: 674–680
  Google Scholar
• 82. Tischkowitz M.D., Hodgson S.V.: Fanconi anemia. J. Med. Genet.,2003, 40, 1–10
  Google Scholar
• 83. Tischkowitz M., Xia B., Sabbaghian N., Reis-Filho J.S., Hamel N., LiG., van Beers E.H., Li L., Khalil T., Quenneville L.A., Omeroglu A., PollA., Lepage P., Wong N., Nederlof P.M., Ashworth A. i wsp.: Analysis ofPALB2/FANCN-associated breast cancer families. Proc. Natl. Acad. Sci.USA, 2007; 104: 6788–6793
  Google Scholar
• 84. Tomaszewska A., Srebniak M., Gnyś A.: Chromosome instabilitysyndromes. Pol. Merkur Lekarski, 2006; 20: 577–581
  Google Scholar
• 85. Verlander P.C., Kaporis A., Liu Q., Zhang Q., Seligsohn U., AuerbachA.D.: Carrier frequency of the IVS4 + 4 A→T mutation of theFanconi anemia gene FAC in the Ashkenazi Jewish population. Blood,1995; 86: 4034–4038
  Google Scholar
• 86. Winter J., Joenje H.: The genetic and molecular basis of Fanconianemia. Mutat. Res., 2009; 668: 11–19
  Google Scholar
• 87. Wu Z.H.: The concept and practice of Fanconi anemia: Fromthe clinical bedside to the laboratory bench. Transl. Pediatr., 2013;2: 112–119
  Google Scholar
• 88. Zen P.R., de Moraes F.N., Rosa R.F., Graziado C., PaskulinG.A.: Clinical characteristics of patients with Fanconianemia. Rev. Paul. Pediatr., 2011; 29: 392–399
  Google Scholar

Full text